Prot #BLU-285-EAP-01: Early Access Program (EAP) for Avapritinib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Project: Research project

Project Details

StatusActive
Effective start/end date7/23/197/23/21

Funding

  • WE Pharma, Inc (Prot #BLU-285-EAP-01)
  • Blueprint Medicines Corporation (Prot #BLU-285-EAP-01)